✦ LIBER ✦

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial

✍ Scribed by Procopio, G; Verzoni, E; Bracarda, S; Ricci, S; Sacco, C; Ridolfi, L; Porta, C; Miceli, R; Zilembo, N; Bajetta, E

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Patient-reported outcomes for axitinib v

✍ Cella, D; Escudier, B; Rini, B; Chen, C; Bhattacharyya, H; Tarazi, J; Rosbrook, 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 501 KB

7107 A randomized, prospective, Phase 2

✍ Procopio, G.; Verzoni, E.; Bracarda, S.; Ricci, S.; Miceli, R.; Bertolini, A.; P 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

A Phase II Trial of Intrapatient Dose-Es

✍ Robert Amato; Jim Zhai; James Willis; Somyata Saxena; Melissa DeFoe 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 705 KB

Phase II Placebo-Controlled Randomized D

✍ Ornstein, D.K.; Finley, D.S. 📂 Article 📅 2007 🏛 Elsevier Science ⚖ 56 KB

Phase I trial of sorafenib in combinatio

✍ Masashi Niwakawa, Katsuyoshi Hashine, Raizo Yamaguchi, Hirofumi Fujii, Yasuo Ham 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 359 KB

Phase II trial of sequential subcutaneou

✍ J. P. Maroto, X. G. del Muro, B. Mellado… 📂 Article 📅 2013 🏛 Springer Milan 🌐 Spanish ⚖ 338 KB